DrugDashboards

Cardene IV

nicardipine hydrochloride · NICARDIPINE HYDROCHLORIDE .2 mg/mL · Injection, Solution · Intravenous · Baxter Healthcare Corporation

NDC 43066-0024-10 · 10 BAG in 1 CARTON / 200 mL in 1 BAG · NDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. One of its named manufacturing plants, Baxter Healthcare Corporation, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$80.00
Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA019734
TE code
AP
Approval date
Jan 30, 1992
Patents / exclusivity
22 patents, 0 exclusivities
TypeNumber / codeExpires
patent7612102Dec 26, 2027
patent9364564Dec 26, 2027
patent7612102Dec 26, 2027
patent9364564Dec 26, 2027
patent7612102Dec 26, 2027
patent7612102Dec 26, 2027
patent9364564Dec 26, 2027
patent9364564Dec 26, 2027
patent11547758Apr 18, 2027
patent8455524Apr 18, 2027
patent7659291Apr 18, 2027
patent10758616Apr 18, 2027

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of nicardipine hydrochloride (Injection, Solution)

LabelerStrengthFirst seenLast seen
Baxter Healthcare CorporationNICARDIPINE HYDROCHLORIDE .2 mg/mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CorporationNICARDIPINE HYDROCHLORIDE .1 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCNICARDIPINE HYDROCHLORIDE 25 mg/10mLJul 15, 2026Sep 3, 2026
American Regent, Inc.NICARDIPINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Archis Pharma LLCNICARDIPINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationNICARDIPINE HYDROCHLORIDE 2.5 mg/10mLJul 15, 2026Sep 2, 2026
Civica, Inc.NICARDIPINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.NICARDIPINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Qilu Pharmaceutical Co., Ltd.NICARDIPINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsNICARDIPINE HYDROCHLORIDE 2.5 mg/mLJul 15, 2026Sep 2, 2026
WG Critical Care, LLCNICARDIPINE HYDROCHLORIDE .1 mg/mLJul 15, 2026Sep 2, 2026
WG Critical Care, LLCNICARDIPINE HYDROCHLORIDE .2 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Cardene IV — NDC 43066-0024-10," retrieved September 3, 2026, https://drugdashboards.com/drug/43066002410.

Free to cite with attribution — see how the data is put together.